First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

The Lancet Oncology

Volumn 17, Issue 7, 2016, Pages 928-942

  Eichhorst, Barbara ^a   Fink, Anna Maria ^a   Bahlo, Jasmin ^a   Busch, Raymonde ^b   Kovacs, Gabor ^a   Maurer, Christian ^a   Lange, Elisabeth ^c   Köppler, Hubert ^d   Kiehl, Michael ^e   Sökler, Martin ^f   Schlag, Rudolf ^g   Vehling Kaiser, Ursula ^h   Köchling, Georg ⁱ   Plöger, Christoph ^j   Gregor, Michael ^k   Plesner, Torben ^l   Trneny, Marek ^m   Fischer, Kirsten ^a   Döhner, Harmut ⁿ   Kneba, Michael ^o   Wendtner, Clemens Martin ^p   Klapper, Wolfram ^q   Kreuzer, Karl Anton ^a   Stilgenbauer, Stephan ⁿ   Böttcher, Sebastian ^o   Hallek, Michael ^a   more..

^a UNIVERSITY OF COLOGNE   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c EVANGELISCHES KRANKENHAUS   (Germany)

^d Private Hematology and Oncology Practice   (Germany)

^e Klinikum Frankfurt Oder   (Germany)

^f UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^g Private Practice   (Germany)

^h Private practice   (Germany)

ⁱ Private Practice   (Germany)

^j Private Orthodontic Practice   (Germany)

^k LUZERNER KANTONSSPITAL   (Switzerland)

^l LILLEBAELT HOSPITAL   (Denmark)

^m CHARLES UNIVERSITY   (Czech Republic)

ⁿ UNIVERSITY OF ULM   (Germany)

^o UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^p Klinikum Schwabing   (Germany)

^q UNIVERSITY OF KIEL   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CYCLOPHOSPHAMIDE; FLUDARABINE; RITUXIMAB; ANTINEOPLASTIC AGENT; VIDARABINE;

ABNORMAL LABORATORY RESULT; ACUTE MYELOBLASTIC LEUKEMIA; ADULT; AGED; ALCOHOL LIVER DISEASE; ALLERGIC DISEASE; ANEMIA; AORTA ANEURYSM; ARTERY OCCLUSION; ARTHRALGIA; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; BACKACHE; BACTERIAL INFECTION; BASAL CELL CARCINOMA; BLADDER CANCER; BREAST CANCER; CALCIFICATION; CANCER OF UNKNOWN PRIMARY SITE; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; COLON CANCER; COLON CARCINOMA; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSTONIA; EPISTAXIS; ESOPHAGUS CANCER; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GLAUCOMA; GLIOBLASTOMA; HEAD AND NECK CANCER; HEART DISEASE; HEPATITIS B; HICCUP; HUMAN; HYPERGLYCEMIA; INFECTION; INJURY; IRON OVERLOAD; KIDNEY CANCER; KIDNEY DISEASE; LEUKOPENIA; LEUKOPLAKIA; LUNG CANCER; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MELANOMA; MENTAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; MYCOSIS; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; NEUTROPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PERIANAL ABSCESS; PETECHIA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CALCIFICATION; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RANDOMIZED CONTROLLED TRIAL; RETINA DETACHMENT; SCROTAL PAIN; SECOND CANCER; SEPSIS; SKIN MANIFESTATION; SOFT TISSUE INJURY; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; THROMBOSIS; THYROID CARCINOMA; URTICARIA; VIRUS INFECTION; ANALOGS AND DERIVATIVES; CANCER STAGING; CLINICAL TRIAL; COMPARATIVE STUDY; FOLLOW UP; IMMUNOLOGY; IMMUNOTHERAPY; INTERNATIONAL COOPERATION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENDAMUSTINE HYDROCHLORIDE; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOTHERAPY; INTERNATIONAL AGENCIES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RITUXIMAB; SURVIVAL RATE; VIDARABINE;

EID: 84969523604     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(16)30051-1     Document Type: Article

References (27)

1. 1 Parikh, SA, Rabe, KG, Kay, NE, et al. Chronic lymphocytic leukemia in young (
2. 2 Keating, MJ, O'Brien, S, Albitar, M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 23 (2005), 4079–4088.
3. 3 Thompson, PA, Tam, CS, O'Brien, SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood 127 (2016), 303–309.
4. 4 Fischer, K, Bahlo, J, Fink, AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood 127 (2016), 208–215.
5. 5 Hallek, M, Fischer, K, Fingerle-Rowson, G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukemia: a randomised, open-label, phase III trial. Lancet 376 (2010), 1164–1174.
6. 6 Strati, P, Wierda, W, Burger, J, et al. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer 119 (2013), 3805–3811.
7. 7 Benjamini, O, Jain, P, Trinh, L, et al. Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes. Leuk Lymphoma 56 (2015), 1643–1650.
8. 8 Fischer, K, Cramer, P, Busch, R, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 30 (2012), 3209–3216.
9. 9 Hallek, M, Cheson, BD, Catovsky, D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 111 (2008), 5446–5456.
10. 10 Extermann, M, Overcash, J, Lyman, GH, Parr, J, Balducci, L, Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16 (1998), 1582–1587.
11. 11 Bottcher, S, Ritgen, M, Fischer, K, et al. Minimal residual disease quantification is an independent predictor of progression-free and overall survival in chronic lymphocytic leukemia: a multivariate analysis from the randomized GCLLSG CLL8 trial. J Clin Oncol 30 (2012), 980–1008.
12. 12 Michallet, A-S, Aktan, M, Schuh, A, et al. Rituximab in combination with bendamustine or chlorambucil for the treatment of chronic lymphocytic leukaemia: primary results from the randomised phase IIIb MaBLe study. Leuk Lymphoma, 56(suppl 1), 2015 abstract 88.
13. 13 Owen, JS, Melhem, M, Passarell, JA, D'Andrea, D, Darwish, M, Kahl, B, Bendamustine pharmacokinetic profile and exposure-response relationships in patients with indolent non-Hodgkin's lymphoma. Cancer Chemother Pharmacol 66 (2010), 1039–1049.
14. 14 Laurenti, L, Innocenti, I, Autore, F, et al. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: a retrospective analysis of real-life practice in Italian hematology departments. Leuk Res 39 (2015), 1066–1070.
15. 15 Pfreundschuh, M, Muller, C, Zeynalova, S, et al. Suboptimal dosing of rituximab in male and female patients with DLBCL. Blood 123 (2014), 640–646.
16. 16 Foon, KA, Mehta, D, Lentzsch, S, et al. Long-term results of chemoimmunotherapy with low-dose fludarabine, cyclophosphamide and high-dose rituximab as initial treatment for patients with chronic lymphocytic leukemia. Blood 119 (2012), 3184–3185.
17. 17 Dartigeas, C, Van Den Neste, E, Berthou, C, et al. Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 28 (2015), 1–7.
18. 18 Smolej, L, Brychtova, Y, Doubek, M, et al. Low-dose FCR is a safe and effective treatment option for elderly/comorbid patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Updated results of Project Q-Lite By Czech CLL Study Group. Blood, 124, 2014 abstract 4670.
19. 19 Mulligan, S, Gill, D, Turner, P, et al. A randomised dose de-escalation study of oral fludarabine, ± oral cyclophosphamide and intravenous rituximab as first-line therapy of fit patients with chronic lymphocytic leukaemia (CLL) aged ≥65 years: final analysis of response and toxicity. Blood, 124, 2014 abstract 3325.
20. 20 Goede, V, Fischer, K, Busch, R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 370 (2014), 1101–1110.
21. 21 Brown, JR, O'Brien, S, Kingsley, CD, et al. Obinutuzumab plus fludarabine/cyclophosphamide or bendamustine in the initial therapy of CLL patients: the phase 1b GALTON trial. Blood 125 (2015), 2779–2785.
22. 22 Byrd, JC, Furman, RR, Coutre, SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 369 (2013), 32–42.
23. 23 Furman, RR, Sharman, JP, Coutre, SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 370 (2014), 997–1007.
24. 24 Chanan-Khan, A, Cramer, P, Demirkan, F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol 17 (2016), 200–211.
25. 25 Zelenetz, A, Robak, T, Coiffier, B, et al. Idelalisib plus bendamustine and rituximab (BR) is superior to BR alone in patients with relapsed/refractory chronic lymphocytic leukemia: results of a phase 3 randomized double-blind placebo-controlled study. Blood, 126, 2015, LBA5.
26. 26 Ladyzynski, P, Molik, M, Foltynski, P, A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia. Cancer Treat Rev 41 (2015), 77–93.
27. 27 Woyach, JA, Smucker, K, Smith, LL, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 123 (2014), 1810–1817.